Claims
- 1. An anti-cancer composition for at least one solid tumor cancerous tissue in a patient mammal comprising:
a first combination of white blood cells harvested from a proposed patient's blood sample which has been stabilized, a suitable growth medium, and said at least one cancerous tissue, said first combination then being stimulated with a mitogen challenging compound, and subsequently centrifuged and washed of said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; a second combination composed of a fresh suitable growth medium combined with said first combination harvest, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, and then incubated, said second combination thereby yielding upon centrifugation a second combination harvest having a supernatant useable for non-vascular injection which contains immune system markers which biochemically signal said proposed patient's white blood cells to reject and biochemically inhibit growth of said cancerous tissue.
- 2. The anti-cancer composition according to claim 1, further comprising:
said mitogen-challenging compound being a plant lectin.
- 3. The anti-cancer composition according to claim 2, further comprising:
said mitogen-challenging compound being PHA.
- 4. The anti-cancer composition according to claim 3, further comprising:
adding cystine to the supernatant in order to augment immune system response.
- 5. A method of treating at least one solid tumor cancerous tissue in a patient mammal comprising the following steps:
administering a supernatant by non-vascular injection which contains immune system markers which biochemically signal said proposed patient's white blood cells to reject and biochemically inhibit growth of said cancerous tissue which supernatant has been created from
a) a first combination of a white blood cells harvested from a proposed patient's blood sample which has been stabilized, a suitable growth medium, and said at least one cancerous tissue, said first combination then being stimulated with a mitogen challenging compound, and subsequently centrifuged and washed of said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; and b) a second combination composed of a fresh suitable growth medium combined with said first combination harvest, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, and then incubated, said second combination upon centrifugation thereby yielding a second combination harvest having said supernatant.
- 6. The method according to claim 5, further comprising:
said mitogen-challenging compound being a plant lectin.
- 7. The method according to claim 6, further comprising:
said mitogen-challenging compound being PHA.
- 8. The method according to claim 7, further comprising:
adding cystine to the supernatant in order to augment immune system response.
- 9. A method of treating at least one solid tumor cancerous tissue in a patient mammal comprising the following steps:
harvesting white blood cells for said proposed patient from a blood sample from said patient and testing said white blood cells to determine pre-incubation immune system marker levels; manufacturing a supernatant for administration by non-vascular injection which contains immune system markers which biochemically signal said proposed patient's white blood cells to reject and biochemically inhibit growth of said cancerous tissue which supernatant has been created from
a) a first combination of a white blood cells harvested from a proposed patient's blood sample which has been stabilized, a suitable growth medium, and said at least one cancerous tissue, said first combination then being stimulated with a mitogen challenging compound, and subsequently centrifuged and washed of said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; and b) a second combination composed of a fresh suitable growth medium combined with said first combination harvest, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, and then incubated, said second combination upon centrifugation thereby yielding a second combination harvest having said supernatant; testing, upon completion of incubation and centrifugation, said supernatant for post-incubation immune system marker levels and comparing said post-incubation immune system marker levels with said pre-incubation immune system marker levels to determine the probable efficacy of said supernatant in treating said at least one solid tumor cancer; and upon favorable mediation of immune system marker levels as between said pre-incubation levels and said post-incubation levels, periodically administering said supernatant by non-vascular injection.
- 10. The method according to claim 9, further comprising:
said immune system markers including IL-2 and IL-8.
- 11. The method according to claim 10, further comprising:
said mitogen-challenging compound being a plant lectin.
- 12. The method according to claim 11, further comprising:
said mitogen-challenging compound being PHA.
- 13. The method according to claim 12, further comprising:
adding cystine to the method of treatment in order to augment immune system response.
- 14. The method according to claim 13, enabling evaluation of variables affecting immune system response to proposed anti-cancer method of treatment and evaluation of efficacy of method of treatment, further comprising the following step:
testing a patient for at least one of a glutathione-S-transferase defect, glutathione level, anti-oxidant capacity, and Karnofsky status.
- 15. The method according to claim 14, for further determining biochemical pathways needing further mediation to enhance cancer method of treatment:
testing a patient for COX-2 expression, and upon lack of mediation of COX-2 expression, administering a selective COX-2 inhibitor.
- 16. The method according to claim 15, for further determining biochemical pathways needing further mediation to enhance cancer method of treatment:
testing isoprostane levels in said patient.
- 17. A method of treating at least one solid tumor cancerous tissue in a patient mammal comprising the following steps:
harvesting white blood cells for said proposed patient from a blood sample from said patient and testing said white blood cells to determine pre-incubation cytokine levels of at least cytokines IL-2 and IL-8; manufacturing a sup ematant for administration by non-vascular injection which contains immune system markers which biochemically signal said proposed patient's white blood cells to reject and biochemically inhibit growth of said cancerous tissue which supernatant has been created from
a) a first combination of a white blood cells harvested from a proposed patient's blood sample which has been stabilized, a suitable growth medium, a mitogen challenging compound, and said at least one cancerous tissue, said first combination then being stimulated with a mitogen challenging compound, and subsequently centrifuged and washed of said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; and b) a second combination composed of a fresh suitable growth medium combined with said first combination harvest, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, and then incubated, said second combination upon centrifugation thereby yielding a second combination harvest having said supernatant; testing, upon completion of incubation and centrifugation, said supernatant for post-incubation cytokine levels and comparing said post-incubation cytokine levels with said pre-incubation cytokine levels to determine the probable efficacy of said supernatant in modulating immune system reponse to said at least one solid tumor cancer; and upon favorable mediation of cytokine levels as between said pre-incubation levels and said post-incubation levels, periodically administering said supernatant by non-vascular injection.
- 18. The method according to claim 17, further comprising:
said mitogen-challenging compound being a plant lectin.
- 19. The method according to claim 18, further comprising:
said mitogen-challenging compound being PHA.
- 20. The method according to claim 19, further comprising:
adding cystine to the method of treatment in order to augment immune system response.
- 21. The method according to claim 20, enabling evaluation of variables affecting immune system response to proposed anti-cancer method of treatment and evaluation of efficacy of method of treatment, further comprising the following step:
testing a patient for at least one of a glutathione-S-transferase defect, glutathione level, anti-oxidant capacity, and Karnofsky status.
- 22. The method according to claim 21, for further determining biochemical pathways needing further mediation to enhance cancer method of treatment:
testing a patient for COX-2 expression, and upon lack of mediation of COX-2 expression, administering a selective COX-2 inhibitor.
- 23. The method according to claim 22, for further determining biochemical pathways needing further mediation to enhance cancer method of treatment:
testing isoprostane levels in said patient.
- 24. An anti-cancer composition for at least one solid tumor cancerous tissue in an immuno-compromised patient mammal comprising:
a first combination of white blood cells harvested from a white blood cell fraction from a blood sample of a non-immuno-compromised mammal of compatible mammalian species and blood type to said patient which sample has been stabilized, a suitable growth medium, and said at least one cancerous tissue, said first combination then being stimulated with a mitogen challenging compound, and subsequently centrifuged and washed of said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; a second combination composed of a fresh suitable growth medium combined with said first combination harvest, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, and then incubated, said second combination thereby yielding upon centrifugation a second combination harvest having a supernatant useable for non-vascular injection which contains immune system markers which biochemically signal said proposed patient's white blood cells to reject and biochemically inhibit growth of said cancerous tissue.
- 25. A method of treating at least one solid tumor cancerous tissue in an immuno-compromised patient mammal comprising the following steps:
separating a white blood cell fraction from a blood sample of a non-immuno-compromised mammal of compatible mammalian species and blood type to said patient; administering a supernatant to said patient by non-vascular injection which contains immune system markers which biochemically signal said proposed patient's white blood cells to reject and biochemically inhibit growth of said cancerous tissue which supernatant has been created from
a) a first combination of said white blood cell fraction harvested from said non-immuno-compromised mammal which has been stabilized, a suitable growth medium, a mitogen challenging compound, and said at least one cancerous tissue, said first combination then being incubated and subsequently centrifuged and washed of said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; and b) a second combination composed of a fresh suitable growth medium combined with said first combination harvest, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, and then incubated, said second combination upon centrifugation thereby yielding a second combination harvest having said supernatant.
- 26. The method according to claim 25, further comprising:
said immune system markers including IL-2 and IL-8.
- 27. The method according to claim 26, further comprising:
said mitogen-challenging compound being a plant lectin.
- 28. The method according to claim 27, further comprising:
said mitogen-challenging compound being PHA.
- 29. The method according to claim 28, further comprising:
adding cystine to the method of treatment in order to augment immune system response.
- 30. A method of treating at least one solid tumor cancerous tissue in an immuno-compromised patient mammal comprising the following steps:
separating a white blood cell fraction from a blood sample of a non-immuno-compromised mammal of compatible mammalian species and blood type to said patient; harvesting white blood cells for said proposed patient from a blood sample from said patient and testing said white blood cells to determine pre-incubation immune system marker levels; manufacturing a supernatant for administration by non-vascular injection which contains immune system markers which biochemically signal said proposed patient's white blood cells to reject and biochemically inhibit growth of said cancerous tissue which supernatant has been created from
a) a first combination of said white blood cell fraction harvested from said non-immuno-compromised mammal which has been stabilized, a suitable growth medium, and said at least one cancerous tissue, said first combination then being stimulated with a mitogen challenging compound, and subsequently centrifuged and washed of said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; and b) a second combination composed of a fresh suitable growth medium combined with said first combination harvest, which second combination is heated at a temperature above said patient's normal body patient at a level to trigger creation of heat shock protein, and then incubated, said second combination upon centrifugation thereby yielding a second combination harvest having said supernatant; testing, upon completion of incubation and centrifugation, said supernatant for post-incubation immune system marker levels and comparing said post-incubation immune system marker levels with said pre-incubation immune system marker levels to determine the probable efficacy of said supernatant in treating said at least one solid tumor cancer; and and upon favorable mediation of immune system marker levels as between said pre-incubation levels and said post-incubation levels, periodically administering said supernatant by non-vascular injection.
- 31. The method according to claim 29, further comprising:
said immune system markers including IL-2 and IL-8.
- 32. The method according to claim 31, further comprising:
said mitogen-challenging compound being a plant lectin.
- 33. The method according to claim 32, further comprising:
said mitogen-challenging compound being PHA.
- 34. The method according to claim 33, further comprising:
adding cystine to the method of treatment in order to augment immune system response.
- 35. The method according to claim 34, enabling evaluation of variables affecting immune system response to proposed anti-cancer method of treatment and evaluation of efficacy of method of treatment, further comprising the following step:
testing a patient for at least one of a glutathione-S-transferase defect, glutathione level, anti-oxidant capacity, and Kamofsky status.
- 36. The method according to claim 35, for further determining biochemical pathways needing further mediation to enhance cancer method of treatment:
testing a patient for COX-2 expression, and upon lack of mediation of COX-2 expression, administering a selective COX-2 inhibitor.
- 37. The method according to claim 36, for further determining biochemical pathways needing further mediation to enhance cancer method of treatment:
testing isoprostane levels in said patient.
- 38. A method of treating at least one solid tumor cancerous tissue in an immuno-compromised patient mammal comprising the following steps:
separating a white blood cell fraction from a blood sample of a non-immuno-compromised mammal of compatible mammalian species and blood type to said patient; harvesting white blood cells for said proposed patient from a blood sample from said patient and testing said white blood cells to determine pre-incubation cytokine levels of at least cytokines IL-2 and IL-8; manufacturing a supernatant for administration by non-vascular injection which contains immune system markers which biochemically signal said proposed patient's white blood cells to reject and biochemically inhibit growth of said cancerous tissue which supernatant has been created from
a) a first combination of said white blood cell fraction harvested from said non-immuno-compromised mammal which has been stabilized, a suitable growth medium,and said at least one cancerous tissue, said first combination then being stimulated with a a mitogen challenging compound, and subsequently centrifuged and washed of said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; and b) a second combination composed of a fresh suitable growth medium combined with said first combination harvest, which second combination is heated at a temperature above said patient's normal body patient at a level to trigger creation of heat shock protein, and then incubated, said second combination upon centrifugation thereby yielding a second combination harvest having said supernatant; testing, upon completion of incubation and centrifugation, said supernatant for post-incubation cytokine levels and comparing said post-incubation cytokine levels with said pre-incubation cytokine levels to determine the probable efficacy of said supernatant in treating said at least one solid tumor cancer; and and upon favorable mediation of levels of cytokines as between said pre-incubation levels and said post-incubation levels, periodically administering said supernatant by non-vascular injection.
- 39. The method according to claim 38, further comprising:
said mitogen-challenging compound being a plant lectin.
- 40. The method according to claim 39, further comprising:
said mitogen-challenging compound being PHA.
- 41. The method according to claim 40, further comprising:
adding cystine to the method of treatment in order to augment immune system response.
- 42. The method according to claim 41, enabling evaluation of variables affecting immune system response to proposed anti-cancer method of treatment and evaluation of efficacy of method of treatment, further comprising the following step:
testing a patient for at least one of a glutathione-S-transferase defect, glutathione level, anti-oxidant capacity, and Karnofsky status.
- 43. The method according to claim 42, for further determining biochemical pathways needing further mediation to enhance cancer method of treatment:
testing a patient for COX-2 expression, and upon lack of mediation of COX-2 expression, administering a selective COX-2 inhibitor.
- 44. The method according to claim 43, for further determining biochemical pathways needing further mediation to enhance cancer method of treatment:
testing isoprostane levels in said patient.
- 45. A composition for creating a comparable first and second fraction for in vitro testing of efficacy of an anti-cancer therapy in a mammal against at least one particular cancer line, said fractions containing immune system markers, said composition comprising:
a first combination of white blood cells and ambient immune system markers harvested from a blood sample for which first combination a set of immune system marker levels is determined, including at least IL-2 and IL-8; a second combination of a fresh growth medium, a portion of said cancerous tissue sample, said first combination, and said vaccine in a suitable growth medium, which is incubated, yielding upon centrifugation a second combination harvest having a supernatant; said supernatant being capable of being compared for levels of immune system markers with levels of immune system markers from said first combination.
- 46. A method of ex vivo rapid testing of efficacy of an anti-cancer therapy in a mammalian patient against at least one particular cancer line, comprising the following steps:
prior to initiation of said therapy, harvesting a blood sample from said patient and separating white blood cells from red blood cells to generate pre-therapy white blood cells; determining for said pre-therapy white blood cells a selected set of immune system marker levels including at least IL-2 and 11-8; subsequent to initiation of therapy according to the proposed therapy regimen, harvesting at least one new sample of said patient's blood and determining for said at least one subsequent sample of white blood cells said selected set of immune system marker levels; gauging successful mediation of immune system marker levels by comparing said selected set of immune system marker levels in said pre-therapy white blood cells with immune system marker levels of at least one of said at least one subsequent sample.
- 47. The method according to claim 40, enabling evaluation of variables affecting immune system response to proposed anti-cancer method of treatment and evaluation of efficacy of method of treatment, further comprising the following step:
testing a patient for at least one of a glutathione-S-transferase defect, glutathione level, anti-oxidant capacity, and Karnofsky status.
- 48. The method according to claim 41, for further determining biochemical pathways needing further mediation to enhance cancer method of treatment:
testing a patient for COX-2 expression, and upon lack of mediation of COX-2 expression, recommending a selective COX-2 inhibitor.
- 49. A method of manufacturing a cytokine modulator for treating at least one solid tumor cancerous tissue in a patient mammal comprising the following steps:
harvesting white blood cells for said proposed patient from a blood sample from said patient; combining white blood cells harvested from a proposed patient's blood sample which has been stabilized, a suitable growth medium, a mitogen challenging compound, and said at least one cancerous tissue, incubating and subsequently centrifuging, and then washing out said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; combining a fresh suitable growth medium with said first combination harvest to generate a second combination, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, incubating such second combination and separating off by centrifugation supernatant generated from such incubation.
- 50. The method according to claim 49, further comprising:
said mitogen-challenging compound being a plant lectin.
- 51. The method according to claim 50, further comprising:
said mitogen-challenging compound being PHA.
- 52. The method according to claim 52, further comprising:
adding cystine to the method of manufacture in order to augment immune system response.
- 53. A method of manufacturing a cytokine modulator for treating at least one solid tumor cancerous tissue in a patient mammal comprising the following steps:
harvesting white blood cells for said proposed patient from a blood sample from said patient and testing said white blood cells to determine pre-incubation immune system marker levels; combining white blood cells harvested from a proposed patient's blood sample which has been stabilized, a suitable growth medium, a mitogen challenging compound, and said at least one cancerous tissue, incubating and subsequently centrifuging, and then washing out said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; combining a fresh suitable growth medium with said first combination harvest to generate a second combination, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, incubating such second combination and separating off by centrifugation supernatant generated from such incubation; testing, upon completion of incubation and centrifugation, said supernatant for post-incubation immune system marker levels and comparing said post-incubation immune system marker levels with said pre-incubation immune system marker levels to determine the probable efficacy of said supernatant in treating said at least one solid tumor cancer.
- 54. The method according to claim 53, further comprising:
said immune system markers including IL-2 and IL-8.
- 55. The method according to claim 54, further comprising:
said mitogen-challenging compound being a plant lectin.
- 56. The method according to claim 55, further comprising:
said mitogen-challenging compound being PHA.
- 57. The method according to claim 56, further comprising:
adding cystine to the method of manufacture in order to augment immune system response.
- 58. A method of manufacturing a cytokine modulator for treating at least one solid tumor cancerous tissue in a patient mammal comprising the following steps:
harvesting white blood cells for said proposed patient from a blood sample from said patient and testing said white blood cells to determine pre-incubation cytokine levels of at least cytokines IL-2 and IL-8; combining white blood cells harvested from a proposed patient's blood sample which has been stabilized, a suitable growth medium, and said at least one cancerous tissue, stimulating with a mitogen challenging compound, and subsequently centrifuging, and then washing out said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; combining a fresh suitable growth medium with said first combination harvest to generate a second combination, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, incubating such second combination and separating off by centrifugation supernatant generated from such incubation; testing, upon completion of incubation and centrifugation, said supernatant for post-incubation cytokine levels and comparing said post-incubation cytokine levels with said pre-incubation cytokine levels to determine the probable efficacy of said supernatant in treating said at least one solid tumor cancer.
- 59. The method according to claim 58, further comprising:
said mitogen-challenging compound being a plant lectin.
- 60. The method according to claim 59, further comprising:
said mitogen-challenging compound being PHA.
- 61. The method according to claim 60, further comprising:
adding cystine to the method of manufacture in order to augment immune system response.
- 62. A method of manufacturing a cytokine modulator for treating at least one solid tumor cancerous tissue in a patient mammal comprising the following steps:
harvesting white blood cells for said proposed patient from a blood sample from said patient and testing said white blood cells to determine pre-incubation cytokine levels of at least cytokines IL-2 and IL-8; combining white blood cells harvested from a proposed patient's blood sample which has been stabilized, a suitable growth medium, and said at least one cancerous tissue, stimulating with a plant lectin, and subsequently centrifuging, and then washing out said plant lectin to yield a first combination harvest of mitogenically challenged white blood cells; combining a fresh suitable growth medium with said first combination harvest to generate a second combination, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, incubating such second combination and separating off by centrifugation supernatant generated from such incubation; testing, upon completion of incubation and centrifugation, said supernatant for post-incubation cytokine levels and comparing said post-incubation cytokine levels with said pre-incubation cytokine levels to determine the probable efficacy of said supernatant in treating said at least one solid tumor cancer.
- 63. A method of manufacturing a cytokine modulator for treating at least one solid tumor cancerous tissue in a patient mammal comprising the following steps:
harvesting white blood cells for said proposed patient from a blood sample from said patient into a tube having blood stabilizer and a thixotropic medium to facilitate discreet harvesting of white blood cells after centrifugation because of improved separation by density medium centrifugation into distinct cell populations; testing said white blood cells to determine pre-incubation cytokine levels of at least cytokines IL-2, IL-8, and IL-10; combining white blood cells harvested from said proposed patient's blood sample which has been stabilized, a suitable growth medium, and said at least one cancerous tissue, stimulating with PHA for one hour, and subsequently centrifuging, and then washing out said PHA with NaCl solution three times to yield a first combination harvest of mitogenically challenged white blood cells; combining a fresh suitable growth medium with said first combination harvest to generate a second combination, which second combination is heated at a temperature for one hour above said patient's normal body temperature at a level to trigger creation of heat shock protein, incubating such second combination for at least 96 hours and separating off by centrifugation supernatant generated from such incubation; testing, upon completion of incubation and centrifugation, said supernatant for post-incubation cytokine levels and comparing said post-incubation cytokine levels with said pre-incubation cytokine levels to determine the probable efficacy of said supernatant in treating said at least one solid tumor cancer.
- 64. A method of manufacturing a cytokine modulator for treating at least one solid tumor cancerous tissue in an immuno-compromised patient mammal comprising the following steps:
separating a white blood cell fraction from a blood sample of a non-immuno-compromised mammal of compatible mammalian species and blood type to said patient; testing said white blood cell fraction to determine pre-incubation immune system marker levels; combining white blood cells from said white blood cell fraction which has been stabilized, a suitable growth medium, and said at least one cancerous tissue, stimulating with a mitogen challenging compound, and subsequently centrifuging, and then washing out said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; combining a fresh suitable growth medium with said first combination harvest to generate a second combination, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, incubating such second combination and separating off by centrifugation supernatant generated from such incubation; testing, upon completion of incubation and centrifugation, said supernatant for post-incubation immune system marker levels and comparing said post-incubation immune system marker levels with said pre-incubation immune system marker levels to determine the probable efficacy of said supernatant in treating said at least one solid tumor cancer.
- 65. A method of manufacturing a cytokine modulator for treating at least one solid tumor cancerous tissue in an immuno-compromised patient mammal comprising the following steps:
separating a white blood cell fraction from a blood sample of a non-immuno-compromised mammal of compatible mammalian species and blood type to said patient; testing said white blood cell fraction to determine pre-incubation cytokine levels of at least cytokines IL-2 and IL-8; combining white blood cells from said white blood cell fraction which has been stabilized, a suitable growth medium, and said at least one cancerous tissue, stimulating with a mitogen challenging compound and subsequently centrifuging, and then washing out said mitogen challenging compound to yield a first combination harvest of mitogenically challenged white blood cells; combining a fresh suitable growth medium with said first combination harvest to generate a second combination, which second combination is heated at a temperature above said patient's normal body temperature at a level to trigger creation of heat shock protein, incubating such second combination and separating off by centrifugation supernatant generated from such incubation; testing, upon completion of incubation and centrifugation, said supernatant for post-incubation cytokine levels and comparing said post-incubation cytokine levels with said pre-incubation cytokine levels to determine the probable efficacy of said supernatant in treating said at least one solid tumor cancer.
- 66. The method according to claim 54, further comprising:
said mitogen-challenging compound being a plant lectin.
- 67. The method according to claim 55, further comprising:
said mitogen-challenging compound being PHA.
- 68. The method according to claim 56, further comprising:
adding cystine to the method of manufacture in order to augment immune system response.
- 69. The composition according to claims 1, 2, 3, 4, 24, and 45, further comprising:
said blood sample being combined in a tube with a thixotropic medium to enable, upon centrifugation, more discreet harvest of said white blood cells harvested for said first combination.
- 70. The method according to claims 5,6,7,8,9,10,11,12,13,17, 18, 19, 20, 22, 23, 25, 26,27,28,29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 40, 41, 43, 44, 48, 49, 50, 51, 52, 53,54,55,56,57,58, 60, 61, 62, 64, 65, 66, 67, and 68, further comprising:
said step of harvesting white blood cells being a harvesting of a blood sample from the patient into a tube having a thixotropic medium to facilitate discreet harvesting of white blood cells after centrifugation because of improved separation by density medium centrifugation into distinct cell populations and centrifugation.
Parent Case Info
[0001] This is a continuation in part pursuant to 37 C.F.R. 1.78 of Prov. Appl. No. 60/263,486 filed on Jan. 23, 2001 and of a provisional application bearing the above name being filed simultaneously to this specification in June, 2001.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
60263486 |
Jan 2001 |
US |
Child |
09880745 |
Jun 2001 |
US |